Global HIV News
Hepatitis 28/04/2012
NICE publishes final guidance on two new drugs for chronic hepatitis C
NICE has issued final guidance recommending boceprevir and telaprevir in combination with peginterferon alfa and ribavirin, as options for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease.
Hepatitis 28/04/2012
Chronic hepatitis B infection associated with twice the risk of liver-related death compared to hepatitis C
This is the first study to clearly demonstrate that the risk of liver-related death is twice as high for chronic hepatitis B compared to chronic hepatitis C in HIV-infected and -uninfected subjects.
World Policy 27/04/2012
Public spending on AIDS could boost Southern African economies, reports AfDB
Southern African governments could use public spending in their battle against the extremely high rates of HIV/AIDS in their countries and still achieve a positive economic impact.
Pharma Industry 27/04/2012
Gilead Sciences announces first quarter 2012 financial results
Product sales of $2.21 billion, up 19 percent over first quarter 2011.
Tuberculosis & Malaria 27/04/2012
Drug-resistant malaria might be spreading in Africa, study suggests
A strain of malaria that is resistant to artemether may be spreading in Africa.
Tuberculosis & Malaria 27/04/2012
Global Fund-led initiative slashes cost of anti-malaria medicines in many African countries
Life-saving malaria treatment can be bought for less than one US dollar.
World Policy 27/04/2012
Confidential documents show tough staff choices at Global Fund
A confidential document shows the terms on which departing staff is being asked to separate from the international organisation.
Hepatitis 27/04/2012
Dynavax reports HEPLISAV(TM) BLA submission
Pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of age.
Access to treatment 27/04/2012
Experts at WHO say patent pools can stimulate research, medicines access
Patent pools are one of the proposals likely to be effective in stimulating new research and development of medicines needed in developing countries.
World Policy 27/04/2012
UNAIDS and ITUC to work together to increase access to HIV services for workers
UNAIDS and ITUC have signed a memorandum of understanding to eliminate stigma and discrimination, protect human rights and facilitate access to HIV prevention, treatment, care and support for workers.
Hepatitis 27/04/2012
FDA to docs: Best to avoid Victrelis with Norvir-boosted HIV protease inhibitors
Victrelis should not be combined with the following Norvir-boosted HIV protease inhibitors: Reyataz, Prezista or Kaletra.
Prevention 27/04/2012
Breast-feeding past 6 months lowers risk for HIV transmission
Breast-feeding beyond 6 months when mother or infant is taking antiretrovirals can prevent HIV transmission.
Hepatitis 27/04/2012
Incidence of hepatitis C re-infection and clearance may be understimated
The incidence of hepatitis C re-infection among high-risk individuals who have spontaneously cleared the infection may be higher than previously assumed.
EMA & FDA 25/04/2012
Stifling new cures: The true cost of lengthy clinical drug trials
Project FDA report.
Treatment 25/04/2012
Community workshop offers practical steps toward a cure for HIV
A cure for HIV will be essential to ending the AIDS pandemic, but science that is focused directly on a cure is still in early stages and will likely require the support of multiple stakeholders to proceed at the fastest pace.
Tuberculosis & Malaria 25/04/2012
U.N. calls for increased collaboration, funding to fight malaria ahead of World Malaria Day on Wednesday
Although malaria deaths have declined significantly in recent years, there is still much to be done to reach the target of zero deaths by 2015.
Tuberculosis & Malaria 25/04/2012
Study linking malaria resurgence, reduction in malaria control programs highlights need for sustained funding
Progress in eradicating malaria is jeopardized if programs to combat the disease are cut.
Prevention 25/04/2012
US biopharma: "nearly 300 vaccines in R&D"
US biopharmaceutical companies are developing nearly 300 vaccines for the prevention and treatment of a wide variety of diseases.
EMA & FDA 25/04/2012
Many pediatric studies remain unpublished
"One of the most important obligations to the children and families who have willingly enrolled in trials is to ensure that their participation can benefit all children. Only timely, complete and readily available clinical trial results can meet this obligation."
Access to treatment 25/04/2012
Book offers timely insights on IP, drugs and public health in developing countries
A recent book comes in time for the international policy debates coming to a head over access to medicines, intellectual property rights and public health in developing countries.
More...
